<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="4"><Row><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><EntityType>Biological</EntityType><IsActiveCompany>true</IsActiveCompany><StatusSortCode>6</StatusSortCode><Action id="419">Factor VIIa agonist</Action><Company id="1002460">PolyTherics Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><HighestDevStatus id="DR">Discovery</HighestDevStatus><ParentCompany id="1096483">Abzena plc</ParentCompany><Status id="DR">Discovery</Status><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><AuthorityGroup>OTHER</AuthorityGroup><EntityType>Biological</EntityType><IsActiveCompany>false</IsActiveCompany><StatusSortCode>6</StatusSortCode><Action id="419">Factor VIIa agonist</Action><Company id="15303">Cantab Biopharmaceuticals Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><HighestDevStatus id="DR">Discovery</HighestDevStatus><ParentCompany id="1014955">Celtic Pharmaceutical Holdings LP</ParentCompany><Status id="DR">Discovery</Status><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><EntityType>Biological</EntityType><IsActiveCompany>true</IsActiveCompany><StatusSortCode>6</StatusSortCode><Action id="419">Factor VIIa agonist</Action><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><HighestDevStatus id="DR">Discovery</HighestDevStatus><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="DR">Discovery</Status><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Indication id="439">Hemophilia</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><AuthorityGroup>OTHER</AuthorityGroup><EntityType>Biological</EntityType><IsActiveCompany>false</IsActiveCompany><StatusSortCode>2</StatusSortCode><Action id="419">Factor VIIa agonist</Action><Company id="15303">Cantab Biopharmaceuticals Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><HighestDevStatus id="DR">Discovery</HighestDevStatus><ParentCompany id="1014955">Celtic Pharmaceutical Holdings LP</ParentCompany><Status id="NDR">No Development Reported</Status><TherapyArea id="142">Hematological disease</TherapyArea></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>